ER 32935
Latest Information Update: 17 Nov 2006
Price :
$50 *
At a glance
- Originator Eisai Co Ltd
- Class Small molecules
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 17 Nov 2006 Discontinued - Preclinical for Hypertension in Japan (PO)
- 18 Nov 1998 No-Development-Reported for Hypertension in Japan (PO)
- 31 Oct 1996 Preclinical development for Hypertension in Japan (PO)